Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Striping artifact removal in VisiumHD data through nuclear counts modeling.

Bioinformatics (Oxford, England)·2026

Same author

Representation learning for multi-modal spatially resolved transcriptomics data.

Bioinformatics (Oxford, England)·2026

Same author

Estimation of Physiological Metrics from Resting ECGs Using Deep Learning in the UK Biobank, Including submaximal exercise derived V̇O <sub>2</sub> max, Body Fat Percentage, and Grip Strength.

medRxiv : the preprint server for health sciences·2026

Same author

Polyadenylation of insulin mRNA by Tent5a regulates pancreatic beta cells.

Nature communications·2026

Same author

Ki-67 promotes circulating tumor cell intravasation and metastasis in breast cancer.

Cell reports·2026

Same author

Prime editing of a pathogenic <i>Scn1a</i> allele ameliorates seizure phenotypes in a GEFS<sup>+</sup> mouse model.

Science translational medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2025

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

Mutant SF3B1 promotes malignancy in PDAC.

Patrik Simmler^1,2, Eleonora I Ioannidi², Tamara Mengis²

¹Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.

|October 12, 2023

Summary

This summary is machine-generated.

The SF3B1^K700E mutation drives pancreatic cancer aggressiveness, particularly with KRAS and p53 mutations. This splicing factor impedes TGF-β1

Keywords:

PDAC mouse model TGFb-signaling apoptosis cancer biology human cancer cells mouse murine PDAC organoids

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Related Experiment Videos

Last Updated: Jul 13, 2025

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Area of Science:

Oncology
Molecular Biology
Cancer Genetics

Background:

The splicing factor SF3B1 is frequently mutated in pancreatic ductal adenocarcinoma (PDAC).
The specific role of the SF3B1^K700E hotspot mutation in PDAC pathogenesis is not well understood.

Purpose of the Study:

To investigate the impact of the SF3B1^K700E mutation on pancreatic cancer development and progression.
To elucidate the molecular mechanisms by which SF3B1^K700E influences PDAC aggressiveness and response to TGF-β1 signaling.

Main Methods:

Utilized murine models to assess the oncogenic potential of Sf3b1^K700E alone and in combination with KRAS and p53 mutations.
Analyzed the expression of TGF-β1-responsive genes and epithelial-mesenchymal transition (EMT) markers in pancreatic tumors.
Investigated the effect of SF3B1^K700E on TGF-β1-induced cell death in pancreatic organoids and cell lines.
Examined the aberrant splicing of downstream targets, such as Map3k7, in SF3B1^K700E-mutated cells.

Main Results:

Sf3b1^K700E alone does not induce pancreatic malignancy but enhances PDAC aggressiveness when co-occurring with KRAS and p53 mutations.
Sf3b1^K700E impacts early pancreatic tumor progression by reducing the expression of TGF-β1-responsive EMT genes.
SF3B1^K700E confers resistance to TGF-β1-induced cell death in pancreatic cells and organoids.
Aberrant splicing of Map3k7 is implicated in the SF3B1^K700E-mediated resistance to TGF-β1.

Conclusions:

SF3B1^K700E functions as an oncogenic driver in PDAC.
This mutation promotes early-stage tumor progression by interfering with the cellular response to tumor-suppressive TGF-β1 signaling.